FUJIFILM Holdings Corporation

FUJIFILM reported Q1 FY2026 revenue of JPY749.5 billion, operating income of JPY75.3 billion, and net income attributable to FUJIFILM Holdings of JPY53.8 billion. Revenue was flat YoY on a reported basis, but up 4.5% YoY on a currency-neutral basis; operating income increased 35.1% YoY on a currency-neutral basis, and net income rose 10.6% YoY on a currency-neutral basis. By segment, healthcare revenue was JPY228.5 billion and operating income JPY4.3 billion; electronics revenue was JPY102.1 billion and operating income JPY22.5 billion; business innovation revenue was JPY273.6 billion and operating income JPY15.6 billion; imaging revenue was JPY145.3 billion and operating income JPY41.8 billion. Cash inflows were JPY104.7 billion, cash outflows were JPY131.6 billion, and adjusted free cash flow was a JPY25.7 billion outflow. For FY2026, management kept guidance unchanged at revenue of JPY3.28 trillion, operating income of JPY331 billion, and net income attributable to FUJIFILM Holdings of JPY262 billion, while factoring in a JPY6 billion negative tariff impact on operating income.

Teiichi Goto emphasized that the quarter benefited from broad-based strength, especially in imaging, Bio CDMO, and semiconductor materials, and said the company is confident in its growth runway. He highlighted long-term Bio CDMO contracts totaling about USD2 billion at the U.S. site, plus steady progress in Denmark, and said these wins support confidence in reaching FY2030 revenue targets. His tone was upbeat but cautious on the macro outlook: he said the environment remains unclear, yet if FX, geopolitics, and U.S. inflation remain manageable, FUJIFILM could exceed the current operating income target.

Masayuki Higuchi said Q1 revenue of JPY749.5 billion and operating income of JPY75.3 billion were both record highs for a first quarter. He noted that revenue exceeded internal plan, with imaging beating expectations by a wide margin and healthcare slightly below plan due to weaker medical systems demand in China and Asia; operating income also beat plan across most businesses, with healthcare the only modest miss. He added that cash inflows were JPY104.7 billion, cash outflows were JPY131.6 billion, and adjusted free cash flow was a JPY25.7 billion outflow, mainly because of capital expenditure and working-capital-related items. On tariffs, he said the company now expects a JPY6 billion hit to operating income for the year, but has offset much of the impact through supply chain changes, cost controls, and pricing actions.

Analysts pressed management on why Q1 operating income was so strong versus plan, whether the full-year forecast still had upside, and how much tariff pressure remains. Management said Q1 outperformed internal plans overall, with imaging and business innovation well ahead and healthcare slightly below due to China medical materials weakness; Goto said the company could exceed the JPY331 billion operating income guide if FX, geopolitics, and U.S. inflation cooperate. On tariffs, management said the main mitigants were shifting imaging production out of China, adjusting pricing on new products, and reducing advertising and other costs, while medical equipment remains the most challenging area because pricing changes take time. Analysts also asked about the PFAS-free ArF resist and CDMO contracts; management said customer interest is strong, the product is close to ready, and the new U.S./Denmark CDMO deals carry higher unit pricing with inflation clauses built in.